MDGL

337.61

1.90% 6.29

시간 외 거래: 337.61

Madrigal Pharmaceuticals Inc (MDGL)

개요 뉴스 가격 이력 옵션 체인 Financials MDGL 왜 하락? 토론 예측 주식 분할

전일 마감가:

$331.32

열려 있는:

$331

하루 거래량:

769.60K

Relative Volume:

2.19

시가총액:

$7.25B

수익:

순이익/손실:

$-510.45M

주가수익비율:

-17.55

EPS:

-19.24

순현금흐름:

$-455.82M

1주 성능:

+55.02%

1개월 성능:

+61.99%

6개월 성능:

+46.89%

1년 성능:

+129.84%

1일 변동 폭

$316.67

$337.63

1주일 범위

$213.71

$337.63

52주 변동 폭

$133.99

$337.63

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

명칭

Madrigal Pharmaceuticals Inc

부문

Healthcare (1182)

산업

Biotechnology (671)

전화

404-380-9263

주소

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

직원

376

트위터

@MadrigalPharma

다음 수익 날짜

2024-10-31

최신 SEC 제출 서류

MDGL's Discussions on Twitter

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2022-12-20	재확인	Oppenheimer	Outperform
2022-12-19	재확인	H.C. Wainwright	Buy
2022-12-19	재확인	Piper Sandler	Overweight
2022-12-19	업그레이드	Raymond James	Underperform → Mkt Perform
2022-07-08	다운그레이드	B. Riley Securities	Buy → Neutral
2021-10-07	개시	Jefferies	Buy
2021-08-06	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-05-20	재개	Goldman	Buy
2020-11-24	재개	Evercore ISI	Outperform
2020-11-06	재확인	H.C. Wainwright	Buy
2020-07-31	개시	Piper Sandler	Overweight
2020-06-05	개시	BMO Capital Markets	Market Perform
2020-05-05	개시	Chardan Capital Markets	Buy
2020-01-30	개시	Canaccord Genuity	Buy
2020-01-09	업그레이드	UBS	Neutral → Buy
2019-11-07	재확인	H.C. Wainwright	Buy
2019-06-25	개시	Stifel	Hold
2019-06-10	업그레이드	B. Riley FBR	Neutral → Buy
2019-02-28	재확인	H.C. Wainwright	Buy
2019-02-22	개시	SVB Leerink	Outperform
2019-01-23	개시	UBS	Neutral
2018-12-14	개시	Wolfe Research	Outperform
2018-12-12	개시	B. Riley FBR	Neutral
2018-11-19	다운그레이드	Raymond James	Mkt Perform → Underperform
2018-11-16	업그레이드	Evercore ISI	In-line → Outperform
2018-09-04	개시	Citigroup	Buy
2018-08-06	다운그레이드	Goldman	Buy → Neutral
2018-06-28	개시	Raymond James	Mkt Perform

모두보기

Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스

11:35 AM

B. Riley Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat

11:35 AM

Nov 04, 2024

Check Out What Whales Are Doing With MDGL - Benzinga

Nov 04, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High on Analyst Upgrade - MarketBeat

Nov 04, 2024

Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations - Yahoo Finance

Nov 04, 2024

What is Leerink Partnrs' Forecast for MDGL FY2028 Earnings? - MarketBeat

Nov 04, 2024

Emerald Advisers LLC Has $5.79 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat

Nov 04, 2024

Nov 03, 2024

Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? - Benzinga

Nov 03, 2024

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion - Seeking Alpha

Nov 03, 2024

Nov 02, 2024

(MDGL) Long Term Investment Analysis - Stock Traders Daily

Nov 02, 2024

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance

Nov 02, 2024

Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - Simply Wall St

Nov 02, 2024

Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts - Yahoo Finance

Nov 02, 2024

Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up - MSN

Nov 02, 2024

Madrigal Pharmaceuticals Announces Strong Q3 2024 Results and Strategic Advances - MSN

Nov 02, 2024

Nov 01, 2024

MDGL stock soars to 52-week high, reaching $299.99 By Investing.com - Investing.com South Africa

Nov 01, 2024

Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat - MSN

Nov 01, 2024

Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets. - Investor's Business Daily

Nov 01, 2024

Madrigal Pharmaceuticals stock jumps on MASH drug hopes - Yahoo Finance

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $441.00 at UBS Group - MarketBeat

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Earnings Results, Beats Estimates By $2.02 EPS - MarketBeat

Nov 01, 2024

MDGL stock soars to 52-week high, reaching $299.99 - Investing.com

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Sees Strong Trading Volume After Strong Earnings - MarketBeat

Nov 01, 2024

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2024 Earnings Call Transcript - MSN

Nov 01, 2024

Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug - Yahoo Finance

Nov 01, 2024